1. Home
  2. PPL vs UTHR Comparison

PPL vs UTHR Comparison

Compare PPL & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PPL Corporation

PPL

PPL Corporation

HOLD

Current Price

$35.09

Market Cap

24.8B

Sector

Utilities

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$487.12

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PPL
UTHR
Founded
1920
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.8B
20.3B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
PPL
UTHR
Price
$35.09
$487.12
Analyst Decision
Buy
Buy
Analyst Count
8
12
Target Price
$40.75
$495.08
AVG Volume (30 Days)
6.6M
461.5K
Earning Date
02-12-2026
10-29-2025
Dividend Yield
3.08%
N/A
EPS Growth
32.44
16.08
EPS
1.47
26.38
Revenue
$8,979,000,000.00
$3,128,400,000.00
Revenue This Year
$7.75
$13.64
Revenue Next Year
$5.47
$5.78
P/E Ratio
$24.03
$18.81
Revenue Growth
8.42
13.50
52 Week Low
$31.22
$266.98
52 Week High
$38.27
$519.99

Technical Indicators

Market Signals
Indicator
PPL
UTHR
Relative Strength Index (RSI) 50.98 46.92
Support Level $34.08 $498.76
Resistance Level $34.89 $519.99
Average True Range (ATR) 0.40 10.97
MACD 0.20 -2.94
Stochastic Oscillator 85.51 13.46

Price Performance

Historical Comparison
PPL
UTHR

About PPL PPL Corporation

PPL is a holding company of regulated utilities in Pennsylvania, Kentucky, and Rhode Island. The Pennsylvania regulated delivery and transmission segment distributes electricity to customers in central and eastern Pennsylvania. In Kentucky, LG&E and KU are involved in regulated electricity generation, transmission, and distribution. LG&E also provides regulated natural gas distribution. Rhode Island Energy operates electric and gas utilities in the state.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: